Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Verastem, Inc. before investing.

In this article, we go over a few key elements for understanding Verastem, Inc.’s stock price such as:

• Verastem, Inc.’s current stock price and volume
• Why Verastem, Inc.’s stock price changed recently
• Upgrades and downgrades for VSTM from analysts
• VSTM’s stock price momentum as measured by its relative strength

About Verastem, Inc. (VSTM)

Before we jump into Verastem, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer’s inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen’s KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Want to learn more about Verastem, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Verastem, Inc..

Verastem, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Verastem, Inc.’s stock price was $8.200.

Verastem, Inc. is up 2.76% from its previous closing price of $7.980.

During the last market session, Verastem, Inc.’s stock traded between $7.720 and $8.210. Currently, there are approximately 100.12 million shares outstanding for Verastem, Inc..

Verastem, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Verastem, Inc. Stock Price History

Verastem, Inc.’s (VSTM) price is currently up 13.57% so far this month.

During the month of September, Verastem, Inc.’s stock price has reached a high of $8.210 and a low of $7.130.

Over the last year, Verastem, Inc. has hit prices as high as $11.245 and as low as $3.430. Year to date, Verastem, Inc.’s stock is up 6.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Verastem, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there were 0 analysts who downgraded Verastem, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Verastem, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Verastem, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Verastem, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Verastem, Inc. (VSTM) by visiting AAII Stock Evaluator.

Relative Price Strength of Verastem, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Verastem, Inc. has a weighted four-quarter relative price strength of 27.07%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Verastem, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Verastem, Inc. Stock Price: Bottom Line

As of September 4, 2026, Verastem, Inc.’s stock price is $8.200, which is up 2.76% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Verastem, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.